Cubicin®/Cubicin® RF(daptomycin) – Expanded indication
September 1, 2017 – The FDA approved Merck’s Cubicin (daptomycin) and Cubicin RF (daptomycin) injections, for the treatment of Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age).
Download PDF
